Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
News Mar 29, 2012
e-Therapeutics plc has announced that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company’s anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.
A phase I trial in the UK will recruit patients with a variety of solid tumours, while a US investigator-led trial will enrol patients with primary or secondary brain cancers.
Further details of each trial will be provided when its first patient is treated.
Professor Malcolm Young, CEO of e-Therapeutics, said: “We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year.”
e-Therapeutics’ latest expectations for its other products are that ETX1153c (for C. difficile infection) will start phase I in Q2 or Q3, that ETS6103 (for major depressive disorder) will enter phase IIb in Q3 and that ETX1153a (for MRSA infection) will start phase I in Q4.
Compound as Effective as FDA-Approved Drugs Against Life-Threatening InfectionsNews
Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.READ MORE
Chemists Design 'Mini-ecosystems' to Test Drug FunctionNews
Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized 'miniecosystems' to quickly see if a molecule can function as a potential therapeutic.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018